Overview

Inhaled Treprostinil for PAH: Open-label Extension

Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Open-label extension of RIN-PH-302.
Phase:
Phase 3
Details
Lead Sponsor:
United Therapeutics
Treatments:
Treprostinil